Review of: "Progression-free survival as a primary end-point: Counting the cost"

Dragos Eugen Georgescu[1]

1 Carol Davila University of Medicine and Pharmacy

Potential competing interests: No potential competing interests to declare.

The title of this study is intresting and it refflects the content. The author performed an exhaustive analysys of recent clinical trials, demonstrating the advantages and disadvantages of using PFS as a determinant endpoint of drug efficacy. The analysis shows that PFS is not ideal surrogate to replace OS as the new gold standard in determining the endoint of drug efficacy. Even though OS can be a difficult endpoint to obtain in some studies, making PFS a more suitable candidate, data regarding quality of life indices and drug safety are also important elements that must not be omitted.

This article shows a thorough review of literature concluding that OS is not a feasible endpoint in all clinical trial, while PFS is not enough when QoL is adversely affected on follow up in some cancers.